Voyager Therapeutics (NASDAQ:VYGR) Stock Price Up 1.4%

Voyager Therapeutics, Inc. (NASDAQ:VYGR) shares rose 1.4% during mid-day trading on Thursday . The stock traded as high as $7.88 and last traded at $7.85. Approximately 140,559 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 925,631 shares. The stock had previously closed at $7.74.

Wall Street Analyst Weigh In

VYGR has been the topic of several research analyst reports. Citigroup initiated coverage on shares of Voyager Therapeutics in a research report on Thursday, March 7th. They issued a “buy” rating and a $16.00 target price on the stock. Wells Fargo & Company raised shares of Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $9.00 to $14.00 in a research report on Tuesday, January 2nd. HC Wainwright initiated coverage on shares of Voyager Therapeutics in a research report on Tuesday, March 19th. They issued a “buy” rating and a $30.00 target price on the stock. Guggenheim initiated coverage on shares of Voyager Therapeutics in a research report on Tuesday, March 26th. They issued a “buy” rating and a $22.00 target price on the stock. Finally, StockNews.com upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, March 9th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $19.33.

Voyager Therapeutics Stock Down 2.3 %

The company’s fifty day moving average is $8.79 and its 200 day moving average is $7.95. The stock has a market cap of $410.51 million, a PE ratio of 2.52 and a beta of 0.96.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $1.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $1.84. The company had revenue of $90.06 million for the quarter, compared to analyst estimates of $4.95 million. Voyager Therapeutics had a net margin of 52.93% and a return on equity of 63.89%. Equities analysts expect that Voyager Therapeutics, Inc. will post -1.64 EPS for the current year.

Institutional Trading of Voyager Therapeutics

A number of hedge funds have recently made changes to their positions in VYGR. Ameritas Investment Partners Inc. acquired a new stake in shares of Voyager Therapeutics during the second quarter worth approximately $30,000. Gladius Capital Management LP acquired a new stake in shares of Voyager Therapeutics during the third quarter worth approximately $25,000. AJOVista LLC acquired a new stake in shares of Voyager Therapeutics during the fourth quarter worth approximately $39,000. UBS Group AG acquired a new stake in shares of Voyager Therapeutics during the first quarter worth approximately $39,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of Voyager Therapeutics during the fourth quarter worth approximately $43,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.